IP Library › Granted Patent US 10,815,208
Granted Patent B2
US 10,815,208 · App. 16/303,650 · Granted Oct 27, 2020

Method for preparing 2-hydroxyl-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative

Inventors: Zhiqiang Feng (Beijing, CN); Xiaoguang Chen (Beijing, CN); Yang Yang (Beijing, CN); Fangfang Lai (Beijing, CN)
Assignees: Institute of Materia Medica, Chinese Academy of Medical Sciences; Tianjin Chase Sun Pharmaceutical Co., LTD
C07D295/155A61P35/00C07C45/61C07C211/29C07C227/12C07C229/36C07C231/12C07C233/36C07C235/34C07C255/54C07C269/02C07C271/64C07C311/05C07D207/08C07D207/16C07D221/00C07D265/30C07D309/14C07D319/16C07D319/18C07D401/14C07D405/12C07D407/12A61K31/165A61K31/277A61K31/36A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,815,208
App. No.
16/303,650
Granted
Oct 27, 2020
Kind
B2
Abstract

Provided is a method for preparing 2-hydroxy-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by formula (I). The method comprises the following steps: (1) preparing 3-aryl-2-substituted toluene derivative 2 by using 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5 or aryl boronate as starting materials; (2) preparing a benzyl halide derivative 3 by using 3-aryl-2-substituted toluene derivative 2 as starting materials; and (3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) by using benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6.

Claims (22)

1. A method for preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I):

wherein the method comprises the following steps:

1) preparing 3-aryl-2-substituted toluene derivative 2 from 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5, or an aryl boronate thereof, as starting materials:

 wherein “a” means that 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5, or an aryl boronate thereof, are subjected to a Suzuki-Miyaura coupling reaction to form 3-aryl-2-substituted toluene derivative 2 in the presence of a palladium catalyst and a base;

2) preparing benzyl halide derivative 3 from 3-aryl-2-substituted toluene derivative 2 as a starting material:

 wherein “b” means that 3-aryl-2-substituted toluene derivative 2 is reacted with a halogenating agent under radical-initiating condition to prepare a benzyl halide derivative 3;

3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) from benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6 as starting materials:

 wherein “c” means that benzyl halide derivative 3 is reacted with 2, 4-dihydroxy-5-substituted benzaldehyde 6 in a weak basic condition to selectively prepare a 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I);

wherein:

R 1 is selected from fluorine, chlorine, bromine, methyl, and cyano;

R 2 is selected from

R 3 is selected from hydrogen, methyl, ethyl, fluorine, chlorine, and bromine;

X selected from bromine, chlorine, and iodine.

2. The method according to claim 1 , wherein the palladium catalyst is selected from zero-valent palladium and divalent palladium compounds.

3. The method according to claim 2 , wherein the zero-valent palladium catalyst is selected from triphenylphosphine palladium and tetrakis(triphenylphosphine)palladium, and the divalent palladium catalyst is PdCl 2 (dppf).

4. The method according to claim 1 , wherein the base is selected from alkali metal carbonate and alkali metal acetate.

5. The method according to claim 4 , wherein the alkali metal carbonate is selected from cesium carbonate, potassium carbonate, and sodium carbonate, and the alkali metal acetate is selected from sodium acetate and potassium acetate.

6. The method according to claim 1 , wherein the halogenating agent is selected from N-bromosuccinimide, N-chlorosuccinimide, phenyltrimethylammonium tribromide, and elemental bromine.

7. The method according to claim 1 , wherein the radical initiating condition is the addition of a radical initiator, or light, or a combination thereof.

8. The method according to claim 7 , wherein the radical initiator is selected from benzoyl peroxide and m-chloroperoxybenzoic acid.

9. The method according to claim 1 , wherein the weak base condition is the addition of an alkali metal hydrogen carbonate or an alkali metal acetate.

10. The method according to claim 9 , wherein the alkali metal hydrogen carbonate is selected from sodium hydrogen carbonate and potassium hydrogen carbonate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2020
From: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
To: TIANJIN CHASE SUN PHARMACEUTICAL CO., LTD; INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Reel/Frame 052353/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2019
From: FENG, ZHIQIANG; CHEN, XIAOGUANG; YANG, YANG; LAI, FANGFANG
To: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Reel/Frame 048891/0325 →
Priority Claims (1)
CN 2016 1 0343960 · May 23, 2016 · national
Continuity (1)
Related Publication 20200181115A1 · Jun 11, 2020
Cited By (3)
US 12,371,433 US 12,497,383 US 12,533,354